Healthcare Industry News: Liberte
News Release - May 11, 2006
Boston Scientific Announces Court Upholds Jury Decisions in Patent Case with J&J
NATICK, Mass., May 11 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) announced that the U.S. District Court in Delaware issued a ruling upholding two jury decisions in a patent case with Johnson & Johnson (J&J) (NYSE: JNJ ). One jury had found that the Company's Express® and TAXUS® Express® products infringed one J&J stent patent and that the Liberte(TM) product infringed the same patent and an additional J&J stent patent. The one J&J patent that was found to be infringed by the Express, TAXUS Express, and Liberte products expired in November, 2005. A different jury had found that J&J's BX Velocity® and Cypher® products infringed a stent patent of the Company. Both juries had found each party's patents valid.The Court also upheld its earlier decision dismissing the TAXUS® Liberte(TM) product from the case, without prejudice. The Court has not yet ruled on the post-trial motions with regard to the Company's drug coating patent, which the second jury also found infringed by the J&J Cypher product.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
